Satsuma Pharms Company Profile
What is the competitive landscape for SATSUMA PHARMS
SATSUMA PHARMS has one approved drug.
There are seven US patents protecting SATSUMA PHARMS drugs.
Drugs and US Patents for Satsuma Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Satsuma Pharms | ATZUMI | dihydroergotamine mesylate | POWDER;NASAL | 217901-001 | Apr 30, 2025 | RX | Yes | Yes | 11,744,967 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Satsuma Pharms | ATZUMI | dihydroergotamine mesylate | POWDER;NASAL | 217901-001 | Apr 30, 2025 | RX | Yes | Yes | 10,792,253 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Satsuma Pharms | ATZUMI | dihydroergotamine mesylate | POWDER;NASAL | 217901-001 | Apr 30, 2025 | RX | Yes | Yes | 10,758,532 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Satsuma Pharms | ATZUMI | dihydroergotamine mesylate | POWDER;NASAL | 217901-001 | Apr 30, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Satsuma Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 4008307 | ⤷ Start Trial |
| Japan | 7366178 | ⤷ Start Trial |
| Japan | 6902583 | ⤷ Start Trial |
| United Kingdom | 2581431 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

